Self-Amplifying RNA Therapy Boosts Heart Repair After Heart Attack | Science

A novel approach to treating heart damage after a myocardial infarction – commonly known as a heart attack – is showing promise in both animal models and, crucially, in larger mammals like pigs. Researchers are exploring the use of self-amplifying RNA to deliver therapeutic proteins directly to the heart, aiming to reduce scar tissue and improve cardiac function. This isn’t about preventing the initial heart attack, but about mitigating the long-term consequences for those who survive them.

Understanding Myocardial Infarction and the Necessitate for New Therapies

Myocardial infarction occurs when blood flow to the heart is blocked, often by a blood clot. This deprives the heart muscle of oxygen, leading to damage or death of cardiac tissue. While prompt treatment, like coronary catheterization and revascularization, can significantly improve outcomes, many patients are left with permanent structural damage, increasing their risk of heart failure. The heart’s limited ability to regenerate tissue makes finding effective therapies for this condition a critical area of research. Currently, treatment focuses on managing symptoms and preventing further complications, but doesn’t address the underlying structural damage.

Self-Amplifying RNA: A New Delivery System

The study, published in Science, focuses on using self-amplifying RNA (saRNA) to deliver the protein pro-atrial natriuretic peptide (proANP). RNA, or ribonucleic acid, is a molecule essential for carrying out the instructions encoded in our genes. SaRNA is a modified form of RNA that, once inside cells, can create multiple copies of itself, amplifying the therapeutic effect. This means a single injection can produce a sustained release of the therapeutic protein. Traditional gene therapy often relies on viral vectors to deliver genes, but saRNA offers a potentially safer and more efficient alternative. The researchers found that a single intramuscular injection of saRNA encoding proANP reduced infarct size – the area of damaged heart tissue – and improved cardiac function in both mice and pigs following a myocardial infarction.

Pig Models: Bridging the Gap to Human Trials

The use of pigs in this research is particularly significant. Pigs share many physiological similarities with humans, making them a valuable “translational” model for testing new therapies. As noted in a separate study characterizing the immune response to myocardial infarction in pigs, Landrace pigs are frequently used in this type of research due to their heart size and anatomy. This contrasts with smaller animal models like mice, where results don’t always translate effectively to humans. The Science study demonstrated that the saRNA therapy improved both global and regional contractility – the heart’s ability to pump blood – and increased muscle mass while reducing scar size in the pig model. These improvements correlated with changes at the cellular level, specifically cardiomyocyte de-differentiation and proliferation, suggesting the therapy was stimulating some degree of heart muscle regeneration.

The Challenge of Uncontrolled Regeneration

However, the research also revealed a critical caveat. While initial results were promising, persistent and uncontrolled expression of the microRNA – in this case, microRNA-199a, which plays a role in cardiomyocyte proliferation – led to sudden arrhythmic death in most of the treated pigs. This occurred alongside the infiltration of poorly differentiated cells into the heart muscle. This finding, also highlighted in research published in Nature, underscores the delicate balance required when attempting to stimulate heart regeneration. The uncontrolled proliferation of cells can disrupt the heart’s electrical system, leading to dangerous arrhythmias. This suggests that careful dosage control and potentially the use of “on-off” switches to regulate gene expression are crucial for the safe and effective application of this therapy.

What Does This Signify for Patients?

It’s important to emphasize that this research is still in its early stages. The findings from animal studies do not automatically translate to humans. However, they do demonstrate that stimulating endogenous cardiomyocyte proliferation – encouraging the heart’s own cells to regenerate – is a feasible goal in large mammals. The challenge now lies in finding ways to achieve this regeneration in a controlled and safe manner. The study highlights the importance of understanding the complex interplay between gene expression, cell differentiation, and cardiac function.

Immune Response and Cardiac Repair

Interestingly, the immune response following a heart attack also appears to play a role in the potential for cardiac repair. Research into the immune response in pigs following myocardial infarction, as detailed in the PubMed study, shows an influx of immune cells into the damaged heart tissue. This includes both myeloid cells (a type of white blood cell) and activated T cells, as well as an increasing proportion of regulatory T cells (Tregs), which help to modulate the immune response. These findings mirror observations in both mice and humans, suggesting a conserved immune response to heart injury. Understanding how the immune system interacts with the heart during repair could lead to new therapeutic strategies, potentially in combination with saRNA therapy.

What Comes Next: Clinical Trials and Refined Approaches

The next steps involve further refining the saRNA delivery system and conducting more preclinical studies to optimize dosage and minimize the risk of adverse effects. Researchers will likely explore strategies to control the duration of gene expression and to promote the differentiation of newly formed cells into mature, functional cardiomyocytes. The goal is to translate these findings into clinical trials in humans. These trials will need to carefully assess the safety and efficacy of the therapy, as well as identify the patients who are most likely to benefit. The path from animal studies to approved therapies is long and complex, but the potential benefits for patients with heart failure are significant.